Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Larkin

Showing results (11-20 of 418) with videos related to

Pageof 42
Sort By:
Expert Review of Anticancer Therapy|June 13, 2017
Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapyAine O'reilly, James Larkin
The Lancet. Oncology|March 30, 2012
Treatment of brain metastases in patients with melanomaRosalie Fisher, James Larkin
Lancet (London, England)|August 24, 2010
Is advanced renal cell carcinoma becoming a chronic disease?James Larkin, Martin Gore
BMJ (Clinical Research Ed.)|April 30, 2026
The NHS and industry partnerships: risky alliancesMargaret McCartney, James Larkin
Expert Review of Clinical Pharmacology|February 23, 2017
Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapyAine O'Reilly, James Larkin
BMJ Clinical Evidence|May 19, 2009
Malignant melanoma (metastatic)James Larkin, Martin Gore
Expert Opinion on Biological Therapy|January 12, 2016
Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanomaLavinia Spain, James Larkin
Frontiers in Oncology|June 2, 2012
Renal cell cancer: what can we learn from pre-operative studies?Rosalie Fisher, James Larkin
EJC Supplements : EJC : Official Journal of EORTC, European Organization for Research and Treatment of Cancer ... [Et Al.]|July 29, 2015
Individualising treatment choices in a crowded treatment algorithmRosalie Fisher, James Larkin
Nature Reviews. Urology|December 4, 2009
Health policy: The UK 'postcode lottery' in renal cell carcinomaJames Larkin, Martin Gore
Pageof 42

Showing results (11-20 of 418) with videos related to

Sort By:
Pageof 42
Expert Review of Anticancer Therapy|June 13, 2017
Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapyAine O'reilly, James Larkin
The Lancet. Oncology|March 30, 2012
Treatment of brain metastases in patients with melanomaRosalie Fisher, James Larkin
Lancet (London, England)|August 24, 2010
Is advanced renal cell carcinoma becoming a chronic disease?James Larkin, Martin Gore
BMJ (Clinical Research Ed.)|April 30, 2026
The NHS and industry partnerships: risky alliancesMargaret McCartney, James Larkin
Expert Review of Clinical Pharmacology|February 23, 2017
Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapyAine O'Reilly, James Larkin
BMJ Clinical Evidence|May 19, 2009
Malignant melanoma (metastatic)James Larkin, Martin Gore
Expert Opinion on Biological Therapy|January 12, 2016
Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanomaLavinia Spain, James Larkin
Frontiers in Oncology|June 2, 2012
Renal cell cancer: what can we learn from pre-operative studies?Rosalie Fisher, James Larkin
EJC Supplements : EJC : Official Journal of EORTC, European Organization for Research and Treatment of Cancer ... [Et Al.]|July 29, 2015
Individualising treatment choices in a crowded treatment algorithmRosalie Fisher, James Larkin
Nature Reviews. Urology|December 4, 2009
Health policy: The UK 'postcode lottery' in renal cell carcinomaJames Larkin, Martin Gore
Pageof 42